Previous 10 | Next 10 |
2024-05-07 21:46:15 ET Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer...
2024-05-07 16:32:16 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects ...
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire First quarter 2024 total revenue of $29.5 million , which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will re...
2024-04-29 07:00:00 ET Summary Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rigel Pharmaceuticals faces both strengths and ris...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymp...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...
2024-03-05 22:20:25 ET Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Offic...
2024-03-05 16:08:23 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report Rigel Pharmaceuticals acquires U.S. rights to Gavreto ...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...